Buy ELTP by Dec 17, 2026.

Elite Pharmaceuticals (ELTP) has an interesting high-risk/high-upside setup: FY2026 revenue: \~$149M, +77% Operating income: \~$49M, +151% Profitable with an established manufacturing facility. Growing portfolio of generic drugs with additional products in development. Pipeline could provide significant future revenue if approvals and launches succeed. Current market cap is only around $269M, leaving room for substantial expansion if earnings continue growing. 🚀 Big Bull Thesis If ELTP can keep launching profitable generics and grow toward $300M–$500M+ revenue, the company could potentially become …